服务热线:400-028-9008
您好!欢迎访问图拉扬公司![登录] [注册]
我的订单

当前位置:首页 > 文献方案 > 解决方案 > 基于电子鼻的尿液挥发组学分析可准确区分膀胱癌与健康对照:一项前瞻性诊断研究
文章导读
膀胱癌(BCa)缺乏可靠的非侵入性诊断工具。尿液挥发性有机化合物(VOCs)已成为具有潜在鉴别价值的生物标志物。我们评估了电子鼻(eNose)平台用于BCa检测的诊断性能。

Electronic nose-based urinary volatilome profiling accurately discriminates bladder cancer from healthy controls: A prospective diagnostic study
Alessio Filianoti et al.

Abstract
Background: Bladder cancer (BCa) lacks reliable non-invasive diagnostic tools. Urinary volatile organic compounds (VOCs) have emerged as potential discriminative biomarkers. We evaluated the diagnostic performance of an electronic nose (eNose) platform for BCa detection.

摘要

背景: 膀胱癌(BCa)缺乏可靠的非侵入性诊断工具。尿液挥发性有机化合物(VOCs)已成为具有潜在鉴别价值的生物标志物。我们评估了电子鼻(eNose)平台用于BCa检测的诊断性能。

Methods: In this prospective single-center study, 192 patients with histologically confirmed BCa and 143 healthy controls were included. Consecutive patients with suspected primary or recurrent BCa were prospectively screened, and first-morning urine samples were collected in a sterile fashion before Trans-urethral resection of bladder tumor (TURBT) or radical cystectomy. Healthy controls were recruited at the institutional outpatient clinic after exclusion of neoplasia and urinary infection. Patients with ongoing gross hematuria or concomitant urinary infection were not enrolled. Urine samples were analyzed using a 32-sensor eNose (Cyranose C320). Principal component analysis (PCA) and canonical discriminant analysis (CDA) were applied. Cross-validated accuracy (CVA) was calculated using the leave-one-out method. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis.

方法: 在这项前瞻性单中心研究中,纳入192例组织学确诊的BCa患者和143例健康对照。连续前瞻性筛查疑似原发性或复发性BCa的患者,并在经尿道膀胱肿瘤电切术(TURBT)或根治性膀胱切除术前,以无菌方式采集晨尿样本。健康对照在机构门诊招募,并在排除肿瘤和尿路感染后纳入。持续存在肉眼血尿或合并尿路感染的患者未纳入。尿液样本使用32个传感器的电子鼻(Cyranose C320)进行分析。应用主成分分析(PCA)和典型判别分析(CDA)。采用留一法计算交叉验证准确率(CVA)。使用受试者工作特征(ROC)分析评估诊断性能。

Results: The eNose achieved a cross-validated accuracy of 87.5% (P < 0.001). Sensitivity and specificity were 81.8% and 95.1%, respectively. The area under the ROC curve (AUC) was 0.926. Reproducibility was confirmed in serial urine samples obtained from the same patients (CVA 87.2%, AUC 0.90). Positive and negative likelihood ratios were 16.69 and 0.19, respectively.

结果: 电子鼻达到87.5%的交叉验证准确率(P < 0.001)。敏感度和特异度分别为81.8%和95.1%。ROC曲线下面积(AUC)为0.926。在取自同一患者的系列尿液样本中证实了重现性(CVA 87.2%,AUC 0.90)。阳性似然比和阴性似然比分别为16.69和0.19。

Conclusions:
Urinary volatilome profiling using an eNose demonstrates high diagnostic accuracy in discriminating BCa patients from healthy individuals. These findings support eNose-based VOC analysis as a promising non-invasive adjunct tool for BCa detection and clinical triage in selected risk-enriched settings, warranting external validation in multicenter studies.

结论: 使用电子鼻进行尿液挥发组学分析在区分BCa患者与健康个体方面表现出高诊断准确性。这些发现支持基于电子鼻的VOC分析作为一种有前景的非侵入性辅助工具,用于选定风险富集环境中的BCa检测和临床分流,值得在多中心研究中进行外部验证。

Keywords: Bladder cancer; Electronic nose; Gas sensor array; Tumor biomarkers; Urinary volatilome; Volatile organic compounds.

关键词: 膀胱癌;电子鼻;气体传感器阵列;肿瘤生物标志物;尿液挥发组学;挥发性有机化合物。

 

*本文内容非商业广告,仅供专业人士参考!